Health Canada has approved Eli Lilly's Mounjaro to lower cardiovascular risk in patients with type 2 diabetes and heart disease.
← Back to news feed
LLY overview
LLY
Eli Lilly and Company
1,382.75
USD
-71.68
(-4.93%)since Nov 16, 2026
News about LLY
6 stories shown
LLYproduct launch
Seeking Alpha
Rhythm Pharmaceuticals shares rose 3.6% following reports that Eli Lilly submitted a rival acquisition bid.
Seeking Alpha
LLYmerger acquisition
Eli Lilly entered into a multibillion-dollar collaboration with Stipple Bio and agreed to acquire Calytrix Bio to expand its oncology portfolio.
Benzinga
LLYproduct launch
Eli Lilly's Zepbound trial showed promising weight loss results in adolescents, though approval for younger patients remains uncertain.
Seeking Alpha
Analysts identify Eli Lilly, Roche, and Merck as attractive Big Pharma stocks, driven by raised guidance and long-term recovery prospects.
Seeking Alpha
LLYproduct launch
China has approved Eli Lilly's GLP-1 weight-loss pill, granting the company a lead over competitor Novo Nordisk.
Seeking Alpha